Tianjin Med J ›› 2016, Vol. 44 ›› Issue (1): 117-120.doi: 10.11958/58834

Previous Articles     Next Articles

Research progress on RLRs in the treatment of multiple sclerosis

LIU Lu, DU Fangteng, WEN Yi, ZHANG Jixiang△   

  1. Department of Gastroenterology, Second Afiliated Hospital, Nanchang University, Nanchang 330006, China
  • Received:2015-04-23 Revised:2015-08-14 Published:2016-01-15 Online:2016-01-15
  • Contact: △Corresponding Author E-mail: jixiangz@tom.com E-mail:6361831@163.com

Abstract: Abstract: At present, the etiology and pathogenesis of multiple sclerosis are unclear. RIG-Ⅰ-like receptors are a new⁃ ly discovered pattern recognition receptors (RLRs), which are located in cytoplasm. They can recognize the helicase of viral dsRNAs, and interact with interferon beta promoter stimulator (IPS)-1 through their caspase activation recruitment domain (CARD), then form IPS-1 signalsome and induce the expression of interferon type Ⅰ (Ⅰ-IFN), thereby initiate innate im⁃ mune response and induce antiviral response. Recent studies have found that mice lacking IPS-1 would develop exacerbated disease and accompanied by markedly higher inflammation, increasing axonal damage and demyelination. Furthermore, initi⁃ ating the RIG-Ⅰ-like helicase receptor on the immune cells can alleviate inflammation and myelin fracture in multiple scle⁃ rosis of mouse model, thus limit the incidence of paralysis. This paper is a review about the research progress on RLRs in the treatment of multiple sclerosis.

Key words: multiple sclerosis, interferon type Ⅰ, review, RIG-Ⅰ-like receptor, IPS